Adding Talazoparib to Enzalutamide Prolongs Imaging-Based PFS in Metastatic Androgen Pathway Modulation-Sensitive Prostate Cancer with Alterations in HRR Genes By Ogkologos - June 15, 2026 149 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-3 study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Countdown to 100,000 OncoLife Survivorship Care Plans: What is a Survivorship... February 25, 2021 New on NCI’s Websites for September 2021 September 1, 2021 Opportunity and mentorship: Our new PhD programme aiming to open-up academia... July 22, 2022 Experimental mRNA Vaccine Hints at Potential Against Glioblastoma June 11, 2024 Load more HOT NEWS Prospective Evaluation of Benefit in Patients with Advanced Cancer Treated with... Research with integrity – all the fun of the FAIR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with... FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma
